- Comment to study: A randomized phase |III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild type (WT) KRAS metastatic colorectal cancer (mCRC) patients: German study AIO KRK-0306(FIRE-3)2013 | First Faculty of Medicine
- Cetuximab in the first line treatment of colorectal cancer2008 | First Faculty of Medicine
- Management of severe infusion reactions after cetuximab2008 | First Faculty of Medicine
- Cetuximab in metastatic mucinous adenocarcinoma of the colon +12016 | First Faculty of Medicine
- Metastatic colorectal cancer and target EGFR inhibition with cetuximab2012 | Faculty of Medicine in Pilsen
- Using cetuximab in first-line conversion therapy for liver metastatic colorectal cancer2013 | Faculty of Medicine in Pilsen
- The role of cetuximab in the treatment of metastatic colorectal cancer2012 | Faculty of Medicine in Pilsen
- Successful management of infusion reaction accompanying the start of cetuximab therapy2007 | Publication without faculty affiliation
- Successful management of infusion reaction accompanying the start of cetuximab therapy2007 | First Faculty of Medicine
- Case report: cetuximab in the 1st line of treatment of colorectal carcinoma2012 | Faculty of Medicine in Pilsen
- Hypomagnesaemia in patients with metastatic colorectal carcinoma treated with cetuximab2012 | Faculty of Medicine in Hradec Králové
- Urinary Neopterin Concentrations During Combination Therapy with Cetuximab in Previously Treated Patients with Metastatic Colorectal Carcinoma2014 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer2015 | Publication without faculty affiliation
- Rapid, deep and long lasting respnose to cetuximab2022 | Third Faculty of Medicine
- Monitoring of KRAS mutation during cetuximab treatment of head and neck squamous cell carcinoma2012 | First Faculty of Medicine
- The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment2016 | Faculty of Medicine in Pilsen
- MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab2015 | Publication without faculty affiliation
- Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients2016 | Faculty of Medicine in Hradec Králové, Central Library of Charles University, First Faculty of Medicine
- A case study of a patient with advanced, KRAS wild-type colorectal carcinoma, treated with cetuximab2013 | Second Faculty of Medicine
- Cetuximab in the treatment of colorectal carcinoma2017 | First Faculty of Medicine
- First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study2011 | Third Faculty of Medicine
- Eye complications of cetuximab therapy2007 | Publication without faculty affiliation
- Eye complications of cetuximab therapy +12007 | Faculty of Medicine in Hradec Králové
- Eye complications of cetuximab therapy2007 | First Faculty of Medicine
- Serum retinol, alpha-tocopherol and systemic inflammatory response in metastatic colorectal carcinoma patients treated with combination chemotherapy and cetuximab2010 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Serum retinol, alpha-tocopherol and systemic inflammatory response in metastatic colorectal carcinoma patients treated with combination chemotherapy and cetuximab2010 | Central Library of Charles University
- The complete response rate of liver metastasis in patients with metatstatic colorectal cancer treated with the systemic chemotherapy FOLFOX and cetuximab2013 | Publication without faculty affiliation
- Management of severe infusion reactions after cetuximab2008 | Faculty of Medicine in Hradec Králové
